Document is current
Any future updates will be listed below
-
Authors
Yehia, Lamis https://orcid.org/0000-0002-6389-3059
Liu, Darren https://orcid.org/0000-0002-6703-1843
Fu, Shuai https://orcid.org/0000-0002-0298-8433
Iyer, Pranav https://orcid.org/0000-0002-1064-1616
Eng, Charis https://orcid.org/0000-0002-3693-5145
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA124570, R01CA118989)
American Cancer Society (RPG-02-151-01-CCE)
Breast Cancer Research Foundation (NA)
- License Information
-
More Information
Article History
Received: 18 November 2020
Revised: 25 February 2021
Accepted: 1 March 2021
First Online: 22 March 2021
Ethics statement
: Usage of patient-derived lymphoblastoid cell lines was approved by the Cleveland Clinic Institutional Review Board (IRB protocol <i>PTEN</i>-8458).
: The authors declare no competing interests.
